Literature DB >> 10871734

Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells.

R Hoyt1, J Szer, A Grigg.   

Abstract

Reports of neurological toxicity of cryopreserved stem cell infusion are infrequent. Three of 179 consecutive patients experienced significant neurological events in this context. Transient global amnesia developed following infusion in one patient and in the other two, cerebral infarction occurred. Profound hypotension, bradyarrhythmias or hypoxia were not associated with any of these episodes. These events may have been related to infused DMSO, which in the non-transplant setting has been associated with neurological toxicity and local infusion of which has resulted in acute vasospasm in animal models. These cases suggest that infusion of cryopreserved stem cells may result in cerebrovascular ischaemia. Bone Marrow Transplantation (2000) 25, 1285-1287.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871734     DOI: 10.1038/sj.bmt.1702443

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  19 in total

Review 1.  Cryopreservation of hematopoietic stem cells.

Authors:  David Berz; Elise M McCormack; Eric S Winer; Gerald A Colvin; Peter J Quesenberry
Journal:  Am J Hematol       Date:  2007-06       Impact factor: 10.047

2.  Respiratory depression and somnolence in children receiving dimethylsulfoxide and morphine during hematopoietic stem cells transplantation.

Authors:  Désirée Caselli; Veronica Tintori; Andrea Messeri; Stefano Frenos; Franco Bambi; Maurizio Aricò
Journal:  Haematologica       Date:  2008-11-10       Impact factor: 9.941

3.  Preservation of stem cells.

Authors:  Jacob Hanna; Allison Hubel
Journal:  Organogenesis       Date:  2009-07       Impact factor: 2.500

4.  Adverse reactions during stem cell infusion in children treated with autologous and allogeneic stem cell transplantation.

Authors:  T H Truong; R Moorjani; D Dewey; G M T Guilcher; N L Prokopishyn; V A Lewis
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

5.  Cryoprotective Effect of Disaccharides on Cord Blood Stem Cells with Minimal Use of DMSO.

Authors:  Santwana Mantri; Shyama Kanungo; P C Mohapatra
Journal:  Indian J Hematol Blood Transfus       Date:  2014-02-23       Impact factor: 0.900

6.  Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment.

Authors:  Nandita Khera; Jack Jinneman; Barry E Storer; Shelly Heimfeld; Megan M O'Meara; Thomas R Chauncey; Stephanie J Lee; Michael Linenberger
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-15       Impact factor: 5.742

7.  Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact.

Authors:  M R Dowling; S Li; B R Dey; S L McAfee; H R Hock; T R Spitzer; Y-B Chen; K K Ballen
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

8.  Transient loss of consciousness in pediatric recipients of dimethylsulfoxide (DMSO)-cryopreserved peripheral blood stem cells independent of morphine co-medication.

Authors:  Paul G Schlegel; Matthias Wölfl; Judith Schick; Beate Winkler; Matthias Eyrich
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

Review 9.  The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursing.

Authors:  Anna Liza Rodriguez; Joseph D Tariman; Toreend Enecio; Stella Marie Estrella
Journal:  Clin J Oncol Nurs       Date:  2007-08       Impact factor: 1.027

10.  Dimethyl sulfoxide (DMSO) produces widespread apoptosis in the developing central nervous system.

Authors:  Jennifer L Hanslick; Karen Lau; Kevin K Noguchi; John W Olney; Charles F Zorumski; Steven Mennerick; Nuri B Farber
Journal:  Neurobiol Dis       Date:  2008-12-03       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.